-
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce key updates on its late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus (“SLE/Lupus”). Highlights Simbec-Orion has been appointed as the Contract Research Organisation (“CRO”), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive due-diligence…
-
Incanthera Secures Commercial Skincare Deal & £1M Fundraise
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 12.7% shareholding. Within the announcement, Incanthera announces a significant commercial skincare deal with Marionnaud (part of the A.S. Watson…
-
Zak Mir – Tim McCarthy
Zak Mir – Tim McCarthy, CEO Immupharma 22 September 2023 Zak Mir talks to Tim McCarthy, Chairman and CEO, Immupharma, about the recent fund raise, highlights of the company’s portfolio, and the main focus of its drug discovery and development strategy – 22 September 2023
-
Result of retail offer and Director shareholding
ImmuPharma Plc is pleased to announce that further to the Company’s announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform (“WRAP”), in addition…
-
Subscriptions to raise £1.35 million; Sharing Agreement; WRAP Retail Offer to raise up to £0.5 million • Related Party Transactions
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions to raise £1.35 million through the issue of 67,500,000 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 2 pence per Ordinary Share (“Issue Price“) utilising existing authorities to allot shares.…
-
WRAP Retail Offer for up to £500,000
WRAP Retail Offer for up to £500,000 ImmuPharma Plc is pleased to announce a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise up to £500,000 (the “WRAP Retail Offer”) through the issue of new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”). Under the WRAP Retail…
-
INTERIM RESULTS for the six months ended 30 June 2023
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £0.8m (30 June 2022: £1.7m) Research and development expenses of £0.8m (30 June 2022: £1.0m) Administrative expenses…
